(Q84773139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Bladder cancer: validating the EORTC risk tables in BCG-treated patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

David D Buethe

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Wade J Sexton

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

16 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

480-481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844905%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2011.118

10 February 2020

exact match

0 references

cites work

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

31 March 2020

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

Updated concepts and treatment of carcinoma in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

How to build and interpret a nomogram for cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.118

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21844905